Day: May 22, 2024

UAB “Orkela,” legal entity code 304099538, registered address at Jogailos St. 4, Vilnius, Republic of Lithuania (the Issuer), whose securities (the Bonds) are listed and admitted to trading on the Bond List of Nasdaq, also the Bonds are being publicly offered under the base prospectus approved by the Bank of Lithuania on 14 November 2023, as amended by first supplement dated 24 November 2024 (the Prospectus). As stated in the Issuer’s public announcement of 15 May 2024, the Issuer is organising a webinar on 22 May 2024 at 10:00 a.m. (meeting link) to discuss the progress of the Issuer’s real estate development project.  During the webinar, the Issuer will also discuss the circumstance that the premises of the building complex under development is intended to be designed not only for educational facility and offices,...

Novaturas Group, the leader in the Baltic tourism market, has announced its results for the first quarter of 2024. In January–March, the company generated revenues of EUR 34.5 mln. This is EUR 3.7 mln. (10%) less than in the corresponding period of 2023. The company’s EBITDA (earnings before interest, taxes, depreciation and amortisation) was EUR 316 thsnd. In January–March, Novaturas Group served a total of 35.7 thsnd. customers in the Baltic States (38 thsnd. in the corresponding period last year). The net profit of the company for January–March amounted to EUR 8 thsnd. In the same period last year, it was EUR 1.57 mln. These changes are due to complex reasons: a lower demand for Egypt and customer caution due to the military conflict in the Middle East, as well as the changed competitive environment resulting in the decline in profit...

  Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASEWyost® (denosumab) and Jubbonti® (denosumab) approved by EC for all indications of denosumab reference medicines Xgeva® and Prolia® EC approval based on robust development program confirming that biosimilar matches reference medicine in terms of safety, efficacy and quality Approved for treatment of cancer-related bone disease and osteoporosis respectivelyBasel, May 22, 2024 – Sandoz, the global leader in generic and biosimilar medicines, today announced that the European Commission (EC) has granted marketing authorization for Wyost®1 (denosumab) and Jubbonti®2 (denosumab), the first and only biosimilar versions of reference medicines Xgeva®*3 and Prolia®*4 in Europe. Wyost® is approved for the treatment of cancer-related bone disease.1 Jubbonti®...

Approximately one in five people worldwide have elevated Lp(a) levels, putting them at increased risk of cardiovascular diseases including myocardial infarction and stroke.1 The Roche Diagnostics Tina-quant® Lp(a) assay measures lipoprotein (a) in a person’s bloodstream, and will be made available on Roche’s installed base of over 90,000 serum work area (SWA) systems worldwide. The test has been developed in collaboration with Amgen.Basel, 22 May 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the Tina-quant® lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) to identify patients who may benefit from innovative Lp(a)-lowering therapy currently in development. Lp(a) is emerging as an important, yet under-recognised, potential risk factor for...

Hydrogen storage systemThe Hexagon Purus’ hydrogen storage system that will be used in Toyota’s heavy-duty fuel cell electric powertrain kit.Battery packThe high voltage battery pack manufactured by Hexagon Purus for Toyota’s heavy-duty fuel cell electric powertrain kitAdvanced Clean Transportation (ACT) Expo, Las Vegas, Wednesday 22 May: Hexagon Purus is pleased to announce it will be supplying components to Toyota North America (TMNA) for serial production of its heavy-duty fuel cell electric powertrain kits. Hexagon Purus will be providing a full hydrogen storage system and high voltage battery pack for the heavy-duty fuel cell electric powertrain kit1. Hexagon Purus’s collaboration with Toyota started in 2017 as Toyota began development of the fuel cell electric powertrain kits for Class 8 trucks, including...

GENT, Belgium, May 22, 2024 (GLOBE NEWSWIRE) — ArcelorMittal and partners Mitsubishi Heavy Industries, Ltd. (MHI), BHP, along with Mitsubishi Development Pty Ltd (Mitsubishi Development) have successfully started operating a pilot carbon capture unit on the blast furnace off-gas at ArcelorMittal Gent in Belgium. The pilot carbon capture unit will operate for one to two years at Gent, to test the feasibility of progress to full-scale deployment of the technology, which would be able to capture a sizeable portion of the Gent site emissions, if successful.  Engineers have been working on site since January to assemble and commission the unit. In October 2022, the four parties announced their collaboration on a multi-year trial of MHI’s carbon capture technology (Advanced KM CDR ProcessTM) at multiple carbon dioxide (CO2) emission...

Wereldhave N.V. (“Wereldhave”) is pleased to announce that Fitch Ratings has assigned a Long-Term Issuer Default Rating (IDR) and senior unsecured rating of ‘BBB’ to Wereldhave. The Outlook on the IDR is Stable. This public rating reflects the company’s strengthened financial position and solid operational performance. Enhanced balance sheet Wereldhave’s balance sheet has shown significant improvement, supported by the strategic acquisition of Polderplein and the related successful share issue in December 2023. These actions have strengthened the company’s financial profile and reduced leverage. Performance of Full Service Centers The transformation of Wereldhave’s shopping centers into Full Service Centers continues to yield positive results. These centers, offering a mix of retail, leisure, and essential services,...

SCOTTSDALE, Ariz., May 21, 2024 (GLOBE NEWSWIRE) — LifeStance Health Group, Inc. (“LifeStance” or the “Company”) (Nasdaq: LFST), one of the nation’s largest providers of virtual and in-person outpatient mental health care, today announced the pricing of a secondary underwritten public offering of 20,000,000 shares of LifeStance’s common stock, par value $0.01 per share (the “Common Stock”) at a public offering price of $6.25 per share, pursuant to a shelf registration statement filed with the Securities and Exchange Commission (the “SEC”). The underwriters will have a 30-day option to purchase up to an additional 3,000,000 shares of Common Stock from certain stockholders of the Company (the “Selling Stockholders”). The Selling Stockholders will receive all of the proceeds from the offering. The Company is not selling any shares...

ROUYN-NORANDA, Quebec, May 21, 2024 (GLOBE NEWSWIRE) — Falco Resources Ltd. (TSX.V: FPC) (“Falco” or the “Corporation”) provides a positive assessment of the public information meeting of the Bureau d’audiences publiques sur l’environnement (“BAPE”) held on May 21st at the Petit Théâtre du Vieux-Noranda. More than 200 people came for information and to ask questions about Falco’s Horne 5 Project (“Falco’s Horne 5 Project” or the “Project”) not counting webcast participants, which demonstrates the population’s high level of interest in the Project for all the surrounding communities. This public information session allowed the population and various organizations to obtain details on the Project and answers on subjects of concern to them. Falco’s team has been engaged and listening to citizens since day one. To that effect, Falco...

WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock at a public offering price of $31.00 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $325.5 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about May 24, 2024, subject to customary closing conditions. In addition, Dyne has granted the underwriters a 30-day option to purchase up to an additional 1,575,000 shares of its...